Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

12730 High Bluff Drive, Suite 400, San Diego, United States

Quantumup Jul. 11 at 3:13 PM

Goldman Sachs, on 7/10,🏁 $SNDX Buy/$18. $INCY $KURA Goldman Sachs said in their initiation report:

0 · Reply

DorianMD Jul. 9 at 5:13 PM

$KURA could be bottom?

0 · Reply

mmtiddy Jul. 9 at 4:53 PM

$KURA Finally some movement

0 · Reply

Christyalmond Jul. 9 at 3:41 PM

$KURA please hold above $6.

0 · Reply

Andy3731 Jul. 9 at 10:11 AM

$KURA less than 3k watchers, surprising. Thought there would have been more eyes on Oncology

0 · Reply

Andy3731 Jul. 9 at 10:10 AM

$KURA, id take that within 12 months.

1 · Reply

Gps_100X_ROI_Potential Jul. 8 at 4:48 PM

$SLS Dr. Zeidner, Leading the SLS009 P2 Trial, was the Lead Clinical Investigator for Revumenib $SNDX - Recently Approved for AML KMT2a patients, based on PH2 data. Dr. Z - echoed Dr. Kadia's, statements regarding SLS009 - SLS009 P2 is in a dire, unmet need, for patients who've failed AZA + VEN and have a 2 to 2.5 month Life Expectancy. FDA is Currently Reviewing 160 Patients worth of SLS009 trial Data, with P2 67% Response Rates, OS Approaching 1 year and NO SIDE EFFECTS. Recall Dr. Kadia Said All 009 needed was 25% - the company is telling anyone who wants to know, its 67%+. $KURA

0 · Reply

Andy3731 Jul. 8 at 11:46 AM

$CADL Im bullish here, based on their pipeline. Ive learned to ignore the noise. Obviously im taking a view towards 2026 rather than a short term play, so i can stand the short term volatility / lack of movement. Im especially interested in CAN-2409 and potential BLA. P2 data was very promising. Recent offering was at $6 and was bought by tutes - so im more than happy with my current average at 5.15. Also have eyes on $KURA and $ARWR - AGAIN taking more of a medium / long term view.

1 · Reply

BigJuicy Jul. 6 at 1:16 AM

$KURA need 50k gain here on my 50,000$ worth of shares

1 · Reply

Gps_100X_ROI_Potential Jul. 3 at 5:24 PM

$SLS Investment Opportunity of a Lifetime - Just the Secondary Asset is worth 15X to 20X the MCAP - RIGHT NOW Dr. Kadia, MD Anderson discussion the Patients in the SLS009 Phase 2 Trial "...The survival is low and so anything, even a 25% or higher response rate to get these people to some sort of maintenance or to a transplant, would be an ideal scenario.“ - Dr. Zeidner said the Same, 009 would be FDA Approved with 25% response Rates or better - The P2A - Data is IN at 67%, with a 350% Increase in Survival and No Side Effects. SLS Updated their Presentation Deck in April - Disclosing a Glimpse of the Phase 2 Expansion Results - "Confirm Results". = SLS009 is Getting FDA Approval and is Worth Some Number of Billions RIGHT NOW. 2 FDA Accelerated Approvals YESTERDAY Based on PH1/2 Trial Results. $SNDX Revumenib and $KURA Ziftomenib also both approved based on P2 data...

0 · Reply

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2025, 12:09 AM EDT - 10 days ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jun 12, 2025, 7:30 AM EDT - 4 weeks ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 2, 2025, 6:00 PM EDT - 5 weeks ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

Jun 1, 2025, 7:00 PM EDT - 5 weeks ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 22, 2025, 5:30 PM EDT - 7 weeks ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 20, 2025, 7:30 AM EDT - 7 weeks ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

May 14, 2025, 10:00 AM EDT - 2 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 6, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 1, 2025, 8:48 PM EDT - 2 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 2 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 2 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 3 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 4, 2025, 10:12 AM EST - 4 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Feb 27, 2025, 4:46 AM EST - 4 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:03 PM EST - 4 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 5 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 6, 2025, 12:05 PM EST - 5 months ago

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Feb 5, 2025, 4:01 PM EST - 5 months ago

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Jan 6, 2025, 4:30 PM EST - 6 months ago

Kura Oncology Announces Senior Executive Promotions

Dec 18, 2024, 1:46 PM EST - 7 months ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 9, 2024, 7:00 AM EST - 7 months ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 2, 2024, 7:30 AM EST - 7 months ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Nov 25, 2024, 7:30 AM EST - 8 months ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 20, 2024, 5:52 PM EST - 8 months ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:00 PM EST - 8 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 9, 2024, 5:54 AM EST - 8 months ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:09 AM EST - 8 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Oct 31, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 29, 2024, 8:00 AM EDT - 9 months ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 24, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Oct 23, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Sep 30, 2024, 6:30 PM EDT - 10 months ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Sep 17, 2024, 7:30 AM EDT - 10 months ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Aug 9, 2024, 2:07 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Second Quarter 2024 Financial Results

Jun 24, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Jun 11, 2024, 2:00 PM EDT - 1 year ago

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

May 29, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 4, 2024, 5:28 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Kura Oncology Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology to Report First Quarter 2024 Financial Results

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Mar 6, 2024, 7:30 AM EST - 1 year ago

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Feb 27, 2024, 10:19 PM EST - 1 year ago

Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript

Quantumup Jul. 11 at 3:13 PM

Goldman Sachs, on 7/10,🏁 $SNDX Buy/$18. $INCY $KURA Goldman Sachs said in their initiation report:

0 · Reply

DorianMD Jul. 9 at 5:13 PM

$KURA could be bottom?

0 · Reply

mmtiddy Jul. 9 at 4:53 PM

$KURA Finally some movement

0 · Reply

Christyalmond Jul. 9 at 3:41 PM

$KURA please hold above $6.

0 · Reply

Andy3731 Jul. 9 at 10:11 AM

$KURA less than 3k watchers, surprising. Thought there would have been more eyes on Oncology

0 · Reply

Andy3731 Jul. 9 at 10:10 AM

$KURA, id take that within 12 months.

1 · Reply

Gps_100X_ROI_Potential Jul. 8 at 4:48 PM

0 · Reply

Andy3731 Jul. 8 at 11:46 AM

1 · Reply

BigJuicy Jul. 6 at 1:16 AM

$KURA need 50k gain here on my 50,000$ worth of shares

1 · Reply

Gps_100X_ROI_Potential Jul. 3 at 5:24 PM

0 · Reply

Dualg Jul. 2 at 11:10 PM

$KURA BVF is one of the best biotech hedge funds, look what company they are adding to their portfolio!

1 · Reply

Andi77 Jul. 2 at 4:58 PM

$AKBA, $SLS, $KURA 💪

0 · Reply

Andi77 Jul. 2 at 3:12 PM

$KURA I've taken a small position here. Looks promising. 94% institutional. I'd be happy with a BO @ $12-15.

1 · Reply

Andi77 Jul. 2 at 3:07 PM

$KURA 💪

0 · Reply

lowfloatscambuster Jul. 2 at 2:06 PM

$KURA valuation is pure madness. But pay attention. Kyowa, at every step, is continuing to make sure that they have operational control over the company. The agreement disclosed in yesterday’s 8-K is more evidence of exactly this. Now, the rub is that the Kyowa exec team and board are not stupid. In this environment, the longer they wait, the lower the takeout price. However, the clock on approval is ticking and therefore, timing is a constraint. $12 buyout is coming within the next six months.

1 · Reply

mmtiddy Jul. 2 at 12:20 PM

$KURA 2nd day notice of this thing jumping by 7% in pre-market on basically no volume. Probably nothing, but just an observation

0 · Reply

BigJuicy Jul. 2 at 2:32 AM

$KURA under 5.5 wait to add and see where it goes

0 · Reply

txandco Jul. 1 at 8:05 PM

$KURA Will add at under $4, right now this thing is looking for new lows.

1 · Reply

roquefort Jul. 1 at 7:30 PM

$KURA Orphan Drug Designation, Breakthrough Therapy Designation, Fast Track Designation, good cash runway, already secured a partner. Everyone's throwing their money at AI and robotics. This should pop on approval, probably before the Nov 30 PDUFA deadline.

0 · Reply

BigJuicy Jul. 1 at 1:18 PM

$KURA surprised this has such a small amount of followers. Will be a good hold

1 · Reply

txandco Jun. 27 at 8:07 PM

$KURA ah volume way above average

1 · Reply

txandco Jun. 27 at 8:03 PM

$KURA busy after hours why?

0 · Reply

Market Cap	550.62M
Revenue (ttm)	53.88M
Net Income (ttm)	-173.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-322.90%
Debt to Equity Ratio	0.03

Volume	1,201,000
Avg Vol	1,298,950
Day's Range	N/A - N/A
Shares Out	86.58M
Stochastic %K	76%
Beta	0.40
Analysts	Strong Sell
Price Target	$25.92